This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Strategies, which met in Lyon, 14–21 November 2017

LYON, FRANCE - 2019
LIST OF PARTICIPANTS

Members

Samar Alhomoud
King Faisal Specialist Hospital & Research Centre
Riyadh
Saudi Arabia

Johannes Blom (Subgroup Chair, Direct Visualization Tests)
Department of Molecular Medicine and Surgery (MMK)
Karolinska Institutet
Regional Cancer Centre Stockholm-Gotland
Stockholm County Council
Stockholm
Sweden

Michael Bretthauer
Clinic of Clinical Effectiveness Research Group
University of Oslo
Oslo
Norway

Jean-Luc Bulliard
Institute of Social and Preventive Medicine
Lausanne University Hospital
Lausanne
Switzerland

Douglas Corley
Division of Research
Kaiser Permanente
Oakland, CA
USA

1 Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Each participant was asked to disclose pertinent research, employment, and financial interests. Current financial interests and research and employment interests during the past 4 years or anticipated in the future are identified here. Minor pertinent interests are not listed and include stock valued at no more than US$ 1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are listed as significant pertinent interests.

2 Michael Bretthauer's research unit has received screening devices free of charge from various companies (and returned them to the manufacturer after the trials) for investigator-initiated and -run screening trials.
Montserrat Garcia Martinez
Catalan Institute of Oncology (ICO)
IDIBELL
Cancer Prevention and Control Program
L’Hospitalet de Llobregat
Spain

Michael Hoffmeister
Division of Clinical Epidemiology and Aging Research
German Cancer Research Center (DKFZ)
Heidelberg
Germany

Rolf Hultcrantz
Department of Medicine
Karolinska Institutet
Stockholm
Sweden

Iris Lansdorp-Vogelaar
Erasmus Medical Center
Rotterdam
The Netherlands

Iris Nagtegaal
Department of Pathology
Radboud University Medical Center
Nijmegen
The Netherlands

Paul Pinsky (Overall Chair)
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health
Bethesda, MD
USA

Linda Rabeneck (Subgroup Chair, Stool-Based Tests)
Cancer Care Ontario
University of Toronto
Toronto, Ontario
Canada

Suleeporn Sangrajrang
National Cancer Institute
Bangkok
Thailand

Peter Sasieni
King’s College London
London
United Kingdom

Robert A. Smith (Subgroup Chair, Emerging Techniques and High-Risk Populations)
American Cancer Society
Atlanta, GA
USA

Robert J.C. Steele
Division of Cancer
Ninewells Hospital and Medical School
Dundee
United Kingdom

Joseph J.Y. Sung
Department of Medicine and Therapeutics
Institute of Digestive Disease
The Chinese University of Hong Kong
Hong Kong Special Administrative Region
China
Participants

Carolina Wiesner (Subgroup Chair, Colorectal Cancer and Screening Practices)
National Cancer Institute (ESE)
Bogotá
Colombia

Ann G. Zauber
Memorial Sloan Kettering Cancer Center
New York, NY
USA

Invited Specialists

Josep M. Augé Fradera
Biochemistry and Molecular Genetics Department
Hospital Clinic of Barcelona
Barcelona
Spain

Douglas Robertson
White River Junction VA Medical Center
White River Junction, VT
USA

Carlo Senore
Piedmont Reference Center for Epidemiology and Cancer Prevention (CPO Piemonte)
Teaching Hospital “Città della Salute e della Scienza di Torino”
Turin
Italy

Representatives

Chisato Hamashima
Cancer Screening Assessment Section
Division of Cancer Screening Assessment and Management
Center for Public Health Sciences
National Cancer Center and Department of Nursing
Faculty of Medical Technology
Teikyo University
Tokyo
Japan

Jae Kwan Jun
Korean National Cancer Center
Goyang-si Gyeonggi-do
Republic of Korea

3 Josep M. Augé Fradera has received significant research support from the Menarini Group, Sysmex Corporation, and Sentinel Diagnostics.
4 Douglas Robertson is a member of the Scientific Advisory Board of Medtronic. He performs some medico-legal consulting work, particularly on delayed diagnosis of colorectal cancer.
5 Carlo Senore’s institution has received equipment support for research from Covidien (previously Given Imaging) and EndoChoice, and received research support from a joint venture of the Piedmont Region and im3D S.p.A.
Each Observer agreed to respect the Guidelines for Observers at IARC Handbooks meetings. Observers did not serve as Meeting Chair or Subgroup Chair, draft or revise any part of the Handbook, or participate in the evaluations. They also agreed not to contact participants before or after the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.
Administrative Assistance

Marieke Dusenberg
Sandrine Egraz
Michel Javin
Helene Lorenzen-Augros
Andreea Spanu

Production Team

Elisabeth Elbers
Fiona Gould
Solène Quennehen

Post-Meeting Assistance

Linda Zutell (Editor for Volume 17)

Post-Meeting Scientific Assistance

Jae Kwan Jun